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Abstract
Objectives To compare the sensitivity of MRI to detect
colorectal cancer liver metastases (CRLM) after ingestion
of manganese-based contrast agent (CMC-001) with that of
a comprehensive intravenous gadobenate dimeglumine
protocol, and to assess the safety and acceptability of oral
manganese.
Methods 20 patients suspected of having 1–6 CRLM were
included prospectively in this randomised cross-over study.
Liver MRI was performed with a one-week interval at 1.5 T
and included T1-w VIBE and T2-HASTE, before and after
administration of 1.6 g CMC-001 or 0.1 mmol/kg
gadobenate dimeglumine. The metastasis-to-liver signal
intensity (SI) ratio was calculated. Standard of reference
was histopathology after surgery, or combination of other
imaging studies and/or follow up. Adverse events (AE) and
clinicolaboratory tests were monitored.
Results Of 44 metastases, 41 were detected after CMC-001
(93%) and 42 after gadobenate dimeglumine (95%). Fifteen
false–positive lesions were found after CMC-001 and 2
after gadobenate dimeglumine. The metastasis-to-liver SI
ratio was significantly higher after CMC-001 than after
gadobenate dimeglumine (0.51 and 0.21 respectively, P<
0.0001). More AE occurred after manganese compared to
gadobenate dimeglumine.
Conclusions CMC-001 is as sensitive as an extensive
intravenous gadobenate dimeglumine protocol in detecting
CRLM. It was relatively well tolerated but had higher rates
of gastrointestinal AE.
Key Points
￿ Liver MRI after ingestion of manganese is highly
sensitive for detecting metastases
￿ High false–positive rate necessitates further evaluation,
in some cases
￿ The MR examination time is short
￿ Oral ingestion of manganese seems safe and relatively
well tolerated by patients
￿ Manganese compounds may be useful for liver metas-
tasis surveillance after colorectal cancer
Keywords Magnetic resonance imaging.Liver.Neoplasm
metastasis.Colorectal neoplasm.Contrast media
Introduction
The liver is the most common site of metastases from the
gastrointestinal tract, including pancreatic, gastric, small
bowel, and colorectal cancers. In surveillance for liver
metastases, the primary imaging technique is computed
tomography (CT) [1, 2]. Contrast-enhanced ultrasound is
also reported to perform well [3]. However, MRI due to its
superior diagnostic sensitivity and specificity when evalu-
ating liver lesions plays a major role [4, 5].
To improve the detection and characterisation of lesions,
a number of intravenous MRI contrast agents have been
developed. Among these, two of the T1-shortening contrast
agents have liver-specific characteristics: gadoxetic acid
(Primovist®) and gadobenate dimeglumine (MultiHance®).
These contrast agents have to be administered intravenously
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DOI 10.1007/s00330-011-2288-yand contain gadolinium, which increases the risk of
nephrogenic systemic fibrosis (NSF) in patients with low
glomerular filtration rate (GFR) [6].
A liver-specific contrast medium that is not adminis-
tered intravenously and which does not contain gadolin-
ium would be of great value for evaluating patients at
high risk of liver metastases. A new contrast medium
where the manganese is administered orally has been
developed [7, 8]. The uptake of manganese from the
bowel is normally very limited, but can be facilitated
when it is mixed with alanine and vitamin D3.T h e
manganese is then extracted from the blood circulation
by the liver and is subsequently excreted with bile [9–11].
The high manganese uptake in the liver by the hepatocytes
significantly decreases their T1 relaxation time, causing
the liver parenchyma to appear bright on T1-weighted
images. Non-functioning hepatocytes and metastases will
not take up manganese and will therefore be of low signal
intensity on T1-weighted images [7, 8, 12].
The primary aim of this phase II trial was to evaluate
whether the sensitivity of the new oral contrast medium to
detect colorectal liver cancer metastases (CRLM) was
comparable to that of a comprehensive intravenous
gadobenate dimeglumine protocol. The secondary aim
was to assess the safety and acceptability of this new agent
(CMC-001).
Material and methods
Population and standard of reference
Local ethics committee approval and informed patient
consent were obtained for this open, randomised cross-
over prospective study in which each patient constituted
his/her own control. Twenty patients, 10 men and 10
women, aged 51–79 years (mean 64 years) were recruited
prospectively and consecutively. All patients had been
referred to the multidisciplinary team for evaluation of 1–
6 suspected CRLMs before partial liver resection. The
suspected metastases had been observed at contrast-
enhanced CT in 17 patients and at MRI in 3 patients. In
addition, nine of the patients had undergone a contrast-
enhanced transabdominal ultrasound. At the final analysis
(histopathology, additional imaging or follow-up) one or
more metastases were found in 16 of the 20 patients; in 4
patients there were no metastases. In total, 44 metastases
were identified (mean size: 19.5 mm, standard deviation:
15.6, size range: 3–73 mm). Metastases were verified at
histopathology after surgery (n=25), at combined evalua-
tion of contrast-enhanced ultrasound and gadobenate
dimeglumine-enhanced MRI by a consensus committee
consisting of radiologists and surgeons at the multidisci-
plinary conference (n=7), contrast-enhanced ultrasound
performed at least 3 months later (n=8), intra-operative
contrast-enhanced ultrasound (n=3) or contrast-enhanced
CT 3 months later (n=1). The absence of metastatic lesion
in four patients was confirmed by histopathology in two, by
combined evaluation of contrast-enhanced ultrasound and
gadobenate dimeglumine-enhanced MRI in one patient and,
finally, by MDCT examination performed three months
later in one patient. In these four patients, the suspected
metastasis had been observed at CT in three patients and at
gadoxetic acid enhanced MRI in one.
Imaging
Two MRI examinations were performed on each patient at an
interval of 1 week; orally administered manganese-based
contrast medium CMC-001 (manganese chloride tetrahydrate
MnCl2(H2O)4, CMC Contrast, Lyngby, Denmark) or intra-
venously administered gadobenate dimeglumine (Multi-
Hance®, Bracco, Milan, Italy) was used in random order,
based on sealed envelopes.
The patients arrived at the MR unit early in the
morning after one night of fasting. Imaging was
performed at 1.5 T (Magnetom Avanto, Siemens Health-
care, Erlangen, Germany), combining the spine and the
flexible body array coil before administration of contrast
medium and either 3 h after oral ingestion of CMC-001
or after intravenous gadobenate dimeglumine using a 5-
phase imaging protocol (unenhanced, arterioportal, por-
tal venous, 5 min and 2 h), serving as our standard
protocol in daily practice. The dose of CMC-001 was
equivalent to 1.6 g MnCl2 a n dw a sd i s s o l v e di n2 0 0 –
400 mL of water. To facilitate its uptake, the manganese is
combined with 1 g alanine and 1600 IU vitamin D3.T h e
dose of gadobenate dimeglumine was 0.1 mmol/kg.
For T1-weighted imaging, axial breath-hold 3D T1-
weighted images [volumetric interpolated breath hold
examination (VIBE), echo time (TE) 2.03–2.09 ms, repe-
tition time (TR) 4.05–4.29 ms, field of view 40 cm and 120
1.8 mm thick slices] were obtained. For T2 imaging, 60
axial half-Fourier acquisition single-shot turbo spin-echo
(HASTE) images with an echo time (TE) 76 ms, repetition
time (TR) 1000 ms, field of view 38×28.5 cm and 4 mm
thick slices) were used. Total MR examination time for
CMC-001 session was about 10 min each for pre- and post-
contrast imaging. At the gadobenate dimeglumine session,
the total MR examination time was 60+10 min (Table 1).
In all cases of contrast-enhanced ultrasound, the
microbubble-containing contrast agent sulphur hexafluoride
(SonoVue®, Bracco, Milan, Italy) was injected in a single
dose of 2.4 mg/ml followed by a flush of 5–10 ml isotonic
saline; when needed, the injection was repeated to evaluate
the whole liver.
634 Eur Radiol (2012) 22:633–641For patient safety, all examinations were evaluated at the
time of the examination by one of the participating
radiologists (N.A.) and the imaging findings were discussed
at the multidisciplinary conference for decision-making.
After a period of at least 6 weeks all examinations were re-
evaluated in consensus by the two participating radiologists
(N.A. and T.B.) for the purposes of the present study. The
participating radiologists were aware that all patients had
been referred for surgical procedure, but did not have
access to previous studies or surgical outcome.
Image evaluation-lesion detection analysis
The unenhanced series were first evaluated, then the
corresponding contrast-enhanced series. In 10 patients, the
CMC-enhanced examination was evaluated first; in the
other 10, the comprehensive gadobenate dimeglumine
examination was evaluated first. Irrespectively of order,
the CMC-001 and the dimeglumine session were evaluated
with an interval of at least 1 week. When evaluating CMC-
enhanced images, both T1-weighted and T2-HASTE
images were used. Criteria for the diagnosis of metastasis
were low signal intensity at T1-weighted images and
slightly high-signal intensity at T2-HASTE images. Criteria
for classifying a lesion as non-metastatic (i.e. haemangioma
or/and cyst) were low-signal intensity at T1-weighted
images and markedly high-signal intensity at T2-HASTE
images. When evaluating gadobenate dimeglumine-
enhanced images, the whole comprehensive protocol was
used. Criteria for the diagnosis of liver metastasis were
slightly hyperintense appearance in the T2-HASTE series,
discrete peripheral rim contrast enhancement in the arterial
and/or portal venous phases, and hypointense appearance in
the liver-specific phase of the contrast enhanced series (2 h
after administration of contrast medium). Criteria for the
diagnosis of haemangioma were presence of discontinuous
nodular peripheral enhancement following intravenous
contrast agent administration and markedly high-signal
intensity at T2-HASTE series. Criteria for the diagnosis of
cyst were absence of enhancement following intravenous
contrast agent administration and markedly high-signal
intensity at T2-HASTE series. The number of metastases
and their greatest diameter were recorded.
Image evaluation-quantitative analysis
The two participating radiologists (N.A. and T.B.) per-
formed the quantitative analysis shortly after the lesion
detection analysis was completed. There were two sets of
unenhanced images of the liver: one before CMC-001 and
one before gadobenate dimeglumine. For the calculations of
lesion signal intensity before contrast-medium administra-
tion, the chronologically first of the two unenhanced series
was used; for the calculations after contrast administration,
only the hepatospecific phases were used (i.e. the T1-
weighted image 3 h after ingestion of CMC-001 or the T1-
weighted image 2 h after intravenous injection of gadobenate
dimeglumine, respectively).
The signal intensity of the metastasis was obtained from
a centrally placed circular ROI with half the diameter of the
metastasis. The signal intensity of the surrounding liver was
obtained from a representative region near the metastasis, in
the same image, on the same anteroposterior level. The
metastasis-to-liver ratio was calculated as:
Metastasis to liver ratio
¼
Liver signal intensity   Metastasis signal intensity
Liver signal intensity
Safety and acceptability assessment
Patients were carefully monitored for occurrence of AE at 1
and 2 h after contrast- medium administration and were
Table 1 The comprehensive protocol used when using gadobenate dimeglumine
Sequence Imaging
plane
Slice thickness
(mm)
TE (ms) TR (ms) Imaging
time
Comment
T2-weighted HASTE Axial 4 76 1000 3 min Respiratory triggering
T2-weighted HASTE Coronal 4 76 1080 3 min Respiratory triggering
True-FISP Axial 4 1.46–1.54 3.43–3.61 18 s Breath-hold
True-FISP Sagittal 4 1.38 3.23–3.30 18 s Breath-hold
T1-weighted in/out of phase Axial 4 5.04/2.38 126 1 min 11 s Respiratory triggering
MRCP Axial 3 678 3339–8086 3 min Respiratory triggering
MRCP Coronal 1.5 678 3383–10546 3 min Respiratory triggering
T1-weighted 3D VIBE Axial 1.8 2.03–2.09 4.05–4.29 22 s Breath-hold
Before and after Gd-injection
1
1 unenhanced, arterioportal, portal venous, 5 min and 2 h post-contrast
Eur Radiol (2012) 22:633–641 635additionally contacted by telephone at 24 and 48 h after
each product administration for a follow-up of any ongoing
or additional AE. AE were judged by the investigator as
mild, moderate, or severe and those judged as having a
reasonable causal relationship to the contrast agents
qualified as adverse drug reactions (ADR). Other safety
variables evaluated both before and at various time points
after contrast-medium administration included clinical
laboratory assessments (serum clinical chemistry, haema-
tology, serology, urinalysis), vital signs (blood pressure and
heart pulse rate), electrocardiogram (ECG) and physical
examination (data not shown).
Statistics
The calculation was based on a one-sample t-test. Non-
parametric tests were assessed by McNemar’s test (number
of metastases after CMC-001 vs. unenhanced and after
gadobenate dimeglumine vs. unenhanced). Parametric test
(comparison of metastasis to liver ratio) was done by using
Student’s paired t-test.
Results
At the unenhanced T1-weighted image series, 27 of 44
metastases were detected (sensitivity 61%, Table 2). After
contrast-medium administration, a statistically significantly
greater number of metastases were detected: after CMC-001,
41 of 44 metastases were detected (sensitivity 93%, P<0.001)
and after gadobenate dimeglumine 42 of 44 metastases were
detected (sensitivity 95%, P<0.001) (Fig. 1). There was no
statistically significant difference in the number of detected
metastases between CMC-001 and gadobenate dimeglumine.
There were more false–positive lesions detected at CMC-001
than at gadobenate dimeglumine (Table 3). A false–positive
result for both CMC-001 and gadobenate dimeglumine-
enhanced liver MRI is presented in Fig. 2,w h i l eaf a l s e –
negative result for CMC-001 and gadobenate dimeglumine is
p r e s e n t e do nF i g s .3 and 4, respectively. The mean
metastasis-to-liver ratio increased from 0.22 (SD 0.16)
before administration of contrast to 0.51 after CMC-001
(SD 0.17) P<0.0001, but was unchanged after gadobenate
dimeglumine [0.21 (SD 0.15) before and 0.21 (SD 0.09)
after] (Table 4).
A total of 38 unique AE were reported in 19 patients.
After CMC-001 administration, there were 31 AE reported
Table 2 The number of liver metastases detected before and after
contrast-medium administration
Unenhanced CMC-001 Gadobenate
dimeglumine
True positive 27
a 41
b 42
c
False negative 17 3 2
False positive 7 15 2
Sensitivity (%) 61 93 95
a–b P<0.001,
a–c P<0.001,
b–c not significant
Fig. 1 A typical case of colo-
rectal liver metastasis. In the T1-
weighted images the metastasis
(black arrow) has lower signal
intensity compared to the
surrounding parenchyma at all
phases: a, b before contrast
administration, c two hours after
intravenous administration of
gadobenate dimeglumine and
d three hours after oral ingestion
of CMC-001. Some grade of
enhancement of the lesion is
observed after intravenous
administration of gadobenate
dimeglumine (c) but not after
ingestion of CMC-001 (d). The
white arrows indicate liver
vessels
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there were 9 AE reported (3 judged to be ADR). The
number of patients with at least 1 AE was 19 after CMC-
001 and 8 after gadobenate dimeglumine (Table 5). The
most common AE were diarrhoea (12 AE in total, 12
after CMC-001 and 0 after gadobenate dimeglumine)
a n dn a u s e a( 4a f t e rC M C - 0 0 1a n d2a f t e rg a d o b e n a t e
dimeglumine). The most common ADR was diarrhoea
(12 after CMC-001 and 0 after gadobenate dimeglu-
mine) followed by supraventricular extrasystoles (1 after
CMC-001 and 0 after gadobenate dimeglumine), back
pain (1 after CMC-001 and 0 after gadobenate dime-
glumine), headache (1 after CMC-001 and 0 after
gadobenate dimeglumine) and urticaria (0 after CMC-
001 and 1 after gadobenate dimeglumine).
The majority of adverse events were mild (20 AE after
CMC-001 and 7 after gadobenate dimeglumine) or moder-
ate (10 AE after CMC-001 and 2 after gadobenate
dimeglumine). One AE (back pain judged to be possibly
related to CMC-001) was recorded as severe in intensity.
No serious AE were reported. There were no clinically
significant changes in clinical laboratory changes, vital
signs, ECG or at physical examination.
Table 3 False–positive lesions
CMC-001 Gadobenate dimeglumine
FNH 4
a
Haemangioma 4
Fibrotic haemangioma 2 2
Vessel 2
Dysfunction/low uptake 2
b
Clips 1
Total 15 2
aall focal nodular hyperplasias (FNH) were observed in the same
patient
bboth false–positive lesions observed in the same patient
Fig. 2 A histopathologically
proven fibrotic haemangioma
(arrow) being falsely classified
as metastasis on both gadoben-
ate dimeglumine and CMC-001
enhanced MRI. In a T2-HASTE
image, the lesion is faintly hy-
perintense. In the T1-weighted
images, both b before and after
injection of gadobenate dime-
glumine (c arterial, d portal
venous and e hepatobiliary
phases) as well as f 3 h after
ingestion of CMC-001, the
lesion has low-signal intensity,
being impossible to differentiate
from metastasis
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The sensitivity to detect CRLM after orally administered
manganese (93%) was comparable to that of intrave-
nously administered gadobenate dimeglumine (95%).
The high level of sensitivity concur with previously
published studies on detection of liver metastases at
MRI using intravenously administered mangafodipir
trisodium [13] and gadobenate dimeglumine [14, 15].
CRLM as small as 3 mm could be detected, regardless of
which of the two liver-specific contrast agents was used.
The novel contrast agent CMC-001 has, therefore, the
potential to be used for surveillance of patients at high risk
of liver metastases, distinguishing those cancer patients
who need more extensive liver evaluation from those who
do not. Such a group of patients are those with colorectal
cancer. In this patient group liver metastases are present in
up to 25% of the patients at the time of diagnosis [16]a n d
in up to 50% five years later [17]. Patients who have
undergone “curative” liver surgery for colorectal cancer
metastases have a high recurrence rate, more than 60%
[18]. Hence, patients with CRLM require follow up
imaging for many years, preferentially with a fast and
sensitive method. However, further studies assessing the
effectiveness of CMC-001 enhanced liver MRI as a
surveillance tool are required. An advantage of CMC-
001 is that it allows patients to self-administer the contrast
agent orally 2–3 h before the imaging acquisition session
and obviating the need for intravenous injection.
There were 15 false–positive results at the CMC-001
s e s s i o nc o m p a r e dw i t h2f a l s e –positive results at the
gadobenate dimeglumine session. This higher false–posi-
tive rate is a downside of CMC-001 compared to
gadobenate dimeglumine-enhanced liver MRI, where addi-
tional information about the contrast behavior of lesions is
obtained at the dynamic phase after contrast injection,
resulting in higher specificity. In clinical practice, this
means that when lesions are detected at CMC-001
Fig. 3 Af a l s e –negative result
for CMC-001 enhanced MRI.
In a T2-HASTE and b unen-
hanced T1-weighted images,
the lesion (arrow)i sh a r d l y
discernible from an adjacent
liver vessel. In the T1 images
after injection of gadobenate
dimeglumine (c arterial, d por-
tal venous and e hepatobiliary
phases), the lesion has clearly
lower signal intensity compared
to the adjacent liver parenchy-
ma. In f the T1-weighted image
3 h after ingestion of CMC-
001, the lesion is difficult to
detect as it is situated in a part
of the liver with decreased
uptake of CMC-001 due to
decreased portal perfusion and/
or hepatobiliary dysfunction
638 Eur Radiol (2012) 22:633–641enhanced liver MRI, further evaluation by more specific
techniques is necessary; once these lesions have been
characterised, CMC-001 enhanced liver MRI should be
highly accurate for detecting new lesions. CMC-001 should
therefore be of special value in patients where repeated
MRI exams are needed, i.e. in the surveillance situation. In
the study setting, the radiologists were not allowed to
evaluate previous examinations or patient history. This is a
limitation of our study, because the number of false–
positive lesions has probably been overestimated.
Fig. 4 A false–negative result
for gadobenate dimeglumine
enhanced MRI (same patient as
in Fig. 3). Both in the a T2-
HASTE image as well as in the
T1-weighted images after injec-
tion of gadobenate dimeglumine
(c arterial, d portal venous and
e hepatobiliary phases, the
lesion is difficult to identify.
However, in the f T1-weighted
image 3 h after ingestion of
CMC-001, the lesion (arrow)
has clearly lower signal intensity
compared to the adjacent paren-
chyma allowing for correct
diagnosis of a metastasis
Table 4 Mean signal intensity (SI), of liver and metastases before and after contrast-medium administration. The SI is in arbitrary units (one
standard deviation within parenthesis)
CMC-001 Gadobenate dimeglumine
Unenhanced 3 h post contrast Unenhanced 2 h post contrast
Liver SI 160 (35) 268 (91)
a 160 (37) 267 (75)
b
Metastasis SI 122 (27) 122 (31)
c 127 (32) 207 (53)
d
Metastasis to liver ratio 0.22 (0.16) 0.51 (0.17)
e 0.21 (0.15) 0.21 (0.09)
f
a-bnot significant
c–dP<0.0001
e-fP<0.0001
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parenchyma before and after contrast-medium administra-
tion, there was no difference in the signal increase after
CMC-001 compared with that after gadobenate dimeglu-
mine (Table 4). However, the metastases did also show
some grade of enhancement after gadobenate dimeglumine,
but not after CMC-001. Thus, there was a significant
increase in the metastasis-to-liver ratio after CMC-001, but
not after gadobenate dimeglumine. In the present study, the
sensitivity to detect CRLM on T1-weighted images without
contrast media was low (61%), which is much lower
compared with previously published data by Choi et al.
[15] with sensitivity of 86% before and 96% after
gadobenate dimeglumine. One possible explanation for
their greater sensitivity before contrast media were admin-
istered can be the fact that the readers in Choi’s study also
had access to T2-weighted images, while in our study
readers evaluated only T1-weighted images at the unen-
hanced session. Interestingly, their sensitivity increased
only to 87% when adding the dynamic phases after
gadobenate dimeglumine injection (excluding the hepato-
biliary phase), and the number of false–positive lesions
increased from 0 to 1. Furthermore, published data from
Kim et al. [14] show that the hepatobiliary (one-hour
delayed) phase had a better diagnostic performance than the
dynamic phase imaging after gadobenate dimeglumine
injection for the detection of liver metastases (sensitivity
of 96% and 77%, respectively). These findings indicate that
the hepatobiliary phase can play an important role in the
evaluation of CRLM.
The dominant excretion of manganese via the hepato-
biliary pathway makes it theoretically attractive for use in
patients with impaired renal function. When measuring
manganese levels in blood levels and urine in healthy
volunteers after ingestion of CMC-001, no significant
increase in manganese concentration was detected [19].
Further safety studies are, however, needed before such
recommendations can be issued.
There were no serious AE. All but one of the AE were
considered by the investigator to be of mild or moderate
intensity and no safety concerns were raised for any of the
two products. The observed adverse events were related to
the high ion-content resulting in gastrointestinal discomfort,
diarrhoea and nausea. We are therefore currently examining
if lowering the dose of MnCl2 tetrahydrate can result in
fewer AE but with a sufficient diagnostic imaging quality.
Apart from the gastrointestinal disorders, a limitation of
using CMC-001 can be the inhomogeneous uptake in cases
of low portal venous perfusion and/or of decreased liver
function increasing the risk for suboptimal enhancement
and diminishing lesion conspicuity (as is the case in Fig. 3).
In our study, all patients were evaluated for liver surgery.
Therefore, a majority of the metastases (25/44) could be
verified at histopathology. However, the remaining 19 lesions
were not considered resectable and therefore they lack
histopathological verification. The final diagnosis of these
had to rely on other imaging studies and on follow up. This is
a limitation of our study and a factor for potential bias and
overestimation of sensitivity. Additionally, our patient cohort,
i.e. those with colorectal cancer and high risk of having liver
metastases, comprise a highly selected study population,
potentially also contributing to an overestimation of sensitiv-
ity. However, these limitations are considered to be of low
impact in the present comparison with the comprehensive
gadobenate dimeglumine protocol.
In conclusion, the sensitivity to detect colorectal cancer liver
metastases at CMC-001 enhanced MRI is comparably high to
that of a comprehensive intravenous gadobenate dimeglumine
protocol; and it is safe, without serious adverse events.
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